PepEvolutionTB-500 Dosage: What the Research Shows
TB-500 · Thymosin Beta-4 fragment
Status & framing. TB-500 is a research peptide associated with thymosin beta-4. It is NOT FDA-approved and has no established human therapeutic dose. Published human evidence is thin; the figures below are conventions and study-derived values presented for education, not advice.
What the research shows
TB-500 is a synthetic fragment linked to thymosin beta-4, studied mostly in animal models of tissue repair. There is no registered human dosing trial, so widely-cited figures are practitioner conventions rather than validated therapeutic doses. These conventions commonly describe a higher weekly "loading" total split across two injections, tapering to a lower maintenance total.
Doses used in studies
Each row is a dose as reported in the cited source, not a recommendation. Superscripts link to sources below.
| Context | Dose studied | Route / frequency |
|---|---|---|
| Practitioner-reported loading convention | ≈2-5 mg per week (often split into 2 doses)[1]⚠ Not from a registered human trial, a convention scaled from preclinical work. | Subcutaneous or intramuscular |
| Practitioner-reported maintenance convention | ≈2-2.5 mg every 1-2 weeks[1]⚠ Convention only. | Subcutaneous or intramuscular |
| Thymosin beta-4 tissue-repair models (preclinical) | Weight-based dosing in animals; not a fixed human figure[1]⚠ Animal data, does not translate to a fixed human dose. | Injectable, in animal models |
Reconstitution & example math
A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. A 2.5 mg dose is then 1 mL, 100 units, i.e. a full U-100 insulin syringe. To keep draws smaller, use less water (e.g. 1 mL → 5 mg/mL, so 2.5 mg = 0.5 mL / 50 units).
Reconstitute with bacteriostatic water and refrigerate. TB-500 doses are often larger (milligram-scale), so plan vial size and water volume so a single draw stays within one syringe.
Route, half-life & timing
Safety & side-effect notes from the literature
- Reported side-effect burden in the informal literature is low, but there are no controlled human safety trials.[1]
- Because thymosin beta-4 influences cell migration and angiogenesis, a theoretical proliferation concern exists; its effect with active malignancy is not established.[1]
- TB-500 is banned in most competitive sport (WADA prohibited list) and is not FDA-approved for human use.[1]
Frequently asked
What dose of TB-500 is used?+
There is no registered human trial. Practitioner conventions commonly describe a loading phase of about 2-5 mg per week split into two injections, tapering to roughly 2-2.5 mg every 1-2 weeks. These are conventions, not validated therapeutic doses.
How do you reconstitute TB-500?+
A common approach is 2 mL of bacteriostatic water into a 5 mg vial (2.5 mg/mL), so a 2.5 mg dose is 1 mL. Using 1 mL of water instead gives 5 mg/mL, keeping a 2.5 mg draw to 0.5 mL (50 units). Refrigerate after mixing.
Is TB-500 FDA-approved?+
No. TB-500 is a research peptide with no FDA-approved human dose, and it is on the WADA prohibited list for sport. Figures here are conventions and study-derived values for education only.
Get the full TB-500 protocol
PepEvolution Pro turns these research ranges into a personalized schedule, a full TB-500 protocol with a week-by-week plan, sourcing shortlist, and COA-checked vendors. Educational, cited, and built on the same methodology.
See what's in Pro →Email me the TB-500 protocol
Get this TB-500 dosing summary plus related reconstitution and sourcing guides. Research/educational only.
Sources & Citations
Primary sources only. Doses are stated as reported, see methodology.
Related
Educational only, not medical advice. Doses on this page are figures used in published research or clinical labeling, presented for education. They are not a prescription or a recommendation to self-administer. Consult a licensed healthcare provider before using any compound.